Astellas may buy mitochondria start-up Mitokyne as part of R&D alliance
This article was originally published in Scrip
Astellas's new research partnership with the private US venture Mitokyne is in line with the Japanese firm's revised R&D strategy, under which it is making more use of external expertise and moving into new therapeutic areas.
You may also be interested in...
Astellas builds on a 2013 collaboration by acquiring Mitobridge. Ardelyx is partnering with Kyowa Hakko Kirin to bring tenapanor to market in Japan. Meanwhile, Depomed, Xoma and Bristol all offload programs before the end of the year.
Asia Deal Watch: RAPT And Hanmi Partner On CCR4 Antagonist Offering Potential In Multiple Cancer Types
RAPT can earn up to $108m in milestones plus sales royalties under the deal. BerGenBio, Piramal partner on developing AML therapy.
Japanese company starts pivotal trial with novel molecule as it looks to build oncology presence.